- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Agfa launches the Security Services Roadmap
Agfa announced the launch of the Security Services Roadmap – a portfolio of solutions to assist IT Managers in addressing security issues.
HIMSS Dallas, TX, February 14, 2005
Agfa announced the launch of the Security Services Roadmap - a portfolio of solutions to assist IT Managers in addressing security issues.
A cornerstone of Agfa's security portfolio is a comprehensive HIPAA compliance assessment and documentation package for healthcare providers. After completing a series of questionnaires, customers have documentation of their risk assessment, prioritized gaps, action items and employee training. The savings in time and consultant fees have delighted those customers who have used Agfa services to achieve HIPAA security compliance for the April 2005 deadline.
"Agfa set the standard for secure data transmission by being the first PACS vendor to pass the U.S. Air Force's requirements in the most comprehensive security test and evaluation procedures in the healthcare IT industry," says Dan Birach, Vice President of Services, Agfa HealthCare. "We've taken that expertise and raised the bar to provide customizable solutions that analyze and document HIPAA security compliance, secure remote service support, safeguard patient confidentiality and simplify the administration of user security profiles."
Agfa will continue to add solutions and services to meet the needs of customers. In the second quarter of 2005, the Windows-based departmental IMPAXTM is expected to successfully complete the rigorous government security evaluation and Agfa plans to add the Systems Management and Reporting Service to the Security Systems Roadmap portfolio. The Systems Management and Reporting Service will help customers enforce software configuration and virus protection policies, with minimal administrative effort. By the end of the summer, Agfa also plans to introduce the Audit Manager, an automated reporting application that tracks various auditing events such as unauthorized access.
End of message
About Agfa
The Agfa-Gevaert Group is one of the world's leading imaging companies. Agfa develops, manufactures and markets analogue and digital systems, intended mainly for the graphics industry and the healthcare markets.
Agfa's headquarters are in Mortsel, Belgium. The company is active in 40 countries and has agents in another 100 countries throughout the world. Together they achieved a turnover of 4,215 million euros in 2003.
Product and company information can be found on Agfa's home page on the World Wide Web at: www.agfa.com.
Agfa, the Agfa rhombus, IMPAX and See More. Do More. are trademarks of Agfa-Gevaert N.V., Belgium or its affiliates. All rights reserved.
Contacts:
Geertrui De Smet
Global PR Manager HealthCare
tel.: +32 (0) 3 444 73 06
fax: +32 (0) 3 444 72 85
e-mail: geertruidesmet@agfapress.com
Jeff Lewis
Media Relations Manager HealthCare, North America
tel.: 201-440-2500 x4192
e-mail: jeff.lewis@agfa.com
Johan Jacobs
Corporate Press Relations Manager
tel.: +32 (0)3 444 80 15
fax: +32 (0)3 444 74 85
e-mail: johan.jacobs@agfa.com
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
